Spread the love

National Science day special


We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma ideas posted today (28/February/2018) will be available to the use of Scientists/Professors/Teachers/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today. Each idea posted will be served first come, first serve basis. Write to admin@genomediscovery.org for more details.

Dr L Boominathan PhD

President, Director & CSO, GBMD.


What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.

What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: Melatonin inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3

Significance of the study:  

This study suggests, for the first time, that  Spermidineby increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing “Spermidine or its analogues, either alone or in combination with other drugs, may be used to treat pulmonary arterial hypertension (Figure 2). Together, this study suggests that, by treating pulmonary hypertensive patients with Spermidineone may prevent pulmonary arterial hypertension

Figure 1. Mechanistic insights into how Spermidine inhibits the development of pulmonary hypertension through regulation of its target genes
Figure 2. The chemical structure of Spermidine

Details of the research findings: 

Idea Proposed/Formulated by:

Dr L Boominathan Ph.D.

Undisclosed mechanistic information: How Spermidine decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L., Molecular therapy for pulmonary arterial hypertension: Spermidine, an endogenous polyamine,  inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 28/February/2018, 10.56 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Spread the love